Mithra Announces 2020 Financial Calendar

Liege, Belgium, 15 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2020 :

  • 9 March 2020 : 2019 Full Year Results
  • 22 April 2020 : 2019 Annual Report
  • 22 May 2020 : Annual General Shareholders Meeting
  • 24 September 2020 : 2020 Interim report

This calendar and all corporate information on the Company, such as its financial statements, events or corporate presentations, is available on the Company’s website in the Investors’ section (investors.mithra.com).

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 24 December 2019 – 07:30 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 1,444,250 new shares on 20 December 2019, in execution of the principle agreement concluded on 30 September with the former owners of Uteron Pharma relating to the remaining payment obligations that Mithra has under the current earnout agreement.

Mithra Receives EUR 2.9 Million in Non-dilutive Funding

Liege, Belgium, 23 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted EUR 2.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by Mr Willy Borsus, Vice President of the Walloon Government and Minister of Economy, Foreign Trade, Research & Innovation, New Technologies, Agriculture and Urban and Spatial Planning.

Mithra to Present at 38th Annual J.P. Morgan Healthcare Conference

Liege, Belgium, 19 December 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Chief Executive Officer Mr. François Fornieri and members of the executive management team will be attending the 38th Annual J.P. Morgan Healthcare Conference in San Francisco from the 13th to the 16th of January 2020.

Mr. Fornieri will present on Thursday, January 16th at 20:30 CET (11:30 Pacific time). To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the Mithra website investors.mithra.com. An archived replay will be available for 30 days beginning 24 hours after the live presentation.

 

Notice of Extraordinary Shareholders Meeting on 29th November 2019

Liege, Belgium, 30 October 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its intention to hold an Extraordinary General Meeting (“EGM”) on the 29 November 2019 at 2:00 PM in Flémalle 57 rue de l’Expansion (Belgium).

Mithra Provides Supplementary Details on Estelle® US Deal with Mayne

Liege, Belgium, 3 October 2019 – 7 :30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today provides supplementary details related to the US deal with Mayne Pharma for Estelle®.

Mithra Announces 2019 Half Year Results

  • Strong revenue growth from continuing operations (+191%) with best first half-year EBITDA since IPO
  • Cash position remains solid at EUR 77.5 million, key for further R&D development
  • Confirmed unique safety profile of Mithra’s innovative contraceptive pill Estelle® following positive results in both Europe/Russia and United States/Canada. Filing with regulatory authorities planned by end of 2019
  • Phase III E4 monotherapy study of Donesta® in menopause ready to start pending agency approvals
Liege, Belgium, 19 September 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces its financial results for the six-month period ending 30 June 2019, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

  • Strengthening of management team with key appointments of Chief Scientific Officer and Plant Manager, to support the strategy execution of Mithra CDMO
  • Consolidation of R&D and manufacturing teams with 30% increase in highly qualified staff since the beginning of the year
  • Donesta® and PeriNesta® Phase III studies ready to begin, pending approval by authorities
  • Launch of production of Estelle® clinical validation batches for both U.S. and EU filing
  • Positive outcome of the registration procedure for Myring™, adding 15 new Market Authorizations in Europe
Liege, Belgium, 16 July 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 29 April 2019 – 17:45 CEST – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 24 April 2019 for an amount of EUR 84,690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015.

Following this capital increase, Mithra now has 37,688,995 outstanding shares carrying voting rights (37,664,245 outstanding shares previously).

Therefore, Mithra publishes the updated following information :

  • Share capital: EUR 27,591,999.58
  • Total number of securities carrying voting rights: 37,668,995 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,668,995 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:
    • Pursuant to the warrant plan of 2 March 2015: 620 warrants giving right to 1,023,000 shares
    • Pursuant to the warrant plan of 5 November 2018 and following the offer of new subscription rights for new members of the Management Team: 1,336,034 warrants giving right to 1,336,034 shares

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

  • Mithra wins the Essenscia Innovation Award, the most prestigious prize for industrial innovation in Belgium
  • Jury of experts recognize the major breakthrough and worldwide potential of this new generation contraceptive pill
  • Capping more than 20 years of research and development, this award was presented by her Royal Highness, the Princess Astrid, during a ceremony at the Palace of the Academies in Brussels

Liege, Belgium, 02 April 2019 – 17:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it won the prestigious essenscia Innovation Award 2019. Awarded every two years by the Federation of Chemistry and Life Sciences, the Innovation Award is the most important prize for industrial innovation in Belgium. It aims to highlight the greatest innovations of Belgian industry and to encourage Belgian companies to continue to invest in innovative and sustainable products.